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INTRODUCTION
Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children. Regarding histopathologic criteria, RMS can be divided into two main subtypes: embryonal and alveolar RMS (eRMS and aRMS, respectively). The majority of aRMS (80-85%) contain one of the reciprocal chromosomal translocations: either t(2;13)(q35;q14) or t(1;13)(p36;q14). These translocations generate the novel fusion genes PAX3-FOXO1 and PAX7-FOXO1, respectively (1, 2) . However, no characteristic translocations have been described in eRMS. The eRMS is typically characterized by loss of heterozygosity on the short arm of chromosome 11 (11p15.5) (3) and gains in chromosomes 2, 7, 8, 11, 12, 13 and 17 are also common in this subtype (4) .
The Notch signaling pathway is an evolutionary conserved pathway that plays a critical role in tissue development in organisms ranging from nematodes to mammals.
The highly conserved Notch gene family encodes 4 cell surface receptors (Notch1, Notch2, Notch3 and Notch4). When the Notch receptor is activated by its ligands (Delta and Jagged in vertebrates), the Notch intracellular domain (NICD) is released by the γ-secretase complex (5) and translocates to the nucleus where it binds to CSL transcription repressors, converting them into transcriptional activators. The targets of these transcription factors in vertebrates are typified by Hes and Hey genes (6, 7) .
The oncogenic potential of the Notch pathway was first described in acute T-cell lymphoblastic leukemia (T-ALL) in the late 1980's (8) . An abnormal up-regulation of the Notch pathway has also been reported in ovarian (9) , breast (10) and other cancers (11) . With respect to pediatric malignancies, Notch signaling appears to contribute essentially to osteosarcoma metastasis (12) and proliferation (13) promotes medulloblastoma cancer stem cell survival (14) and contributes to angiogenesis in neuroblastoma (15) .
In the last decade, the use of pharmacologic inhibitors of the γ-secretase complex, which inhibit activation of the four Notch receptors, has been reported.
Gamma-secretase inhibitors (GSIs) block the generation of the active form of Notch: the Notch intra-cytoplasmatic domain (NICD) (16) . In recent decades, several GSIs have been actively studied as potential inhibitors of the generation of the β-amyloid peptide associated with Alzheimer´s disease (17) . More recently, some GSIs have begun to be studied in phase I trials for patients with advanced breast cancer and acute T-cell leukemias (18, 19) . and Hs00232618_m1, respectively). The housekeeping gene TBP (assay Hs00172424_m1) was used as internal control. Quantification of relative levels of each mRNA analyzed was performed by the method of Livak and Schmittgen (22) . All samples were tested in triplicate.
Western blot analysis and immunohistochemistry
Western blot: Cells were homogenized in lysis buffer (50mM Tris-HCl, pH 7.4, 150mM
NaCl, 1mM PMSF, 1mM EDTA, 5mg/ml aprotinin, 5mg/ml leupeptin, 1% Triton X-100, 1% sodium deoxycholate and 0.1% SDS) and incubated for 4 min at 90ºC and the total protein content was measured (DC assay kit, Bio-Rad Laboratories 
Cell cycle and apoptosis
One million cells were grown for 3 days in MEM media supplemented with the appropriate GSI or DMSO (control) and harvested with trypsin. For cell cycle, cells
were fixed in 70% ethanol, treated with 100μg/ml RNase A and stained for 1 hour at room temperature with 1μg/ml propidium iodide. Apoptosis was detected using the annexin-V apoptosis kit (BD Biosciences) following manufacturer's instructions. Cells were analyzed in a FacsCalibur cytometer (BD Biosciences).
Transfection with dnMAML1
Cells were transfected using FuGENE 6 transfection reagent (ROCHE, Basel, Switzerland) with dominant negative dnMAML1-GFP or GFP alone both cloned in the plasmidic vector pEGFP (Clontech Laboratories, CA, USA). Stably-transfected cells were selected for vector incorporation over 3 weeks in MEM culture media containing 2.0mg/ml G418 (Sigma-Aldrich).
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Notch pathway activation correlates with invasive phenotype in RMS cells
Although the RMS cell lines analyzed significantly expressed Notch1, Notch2 and Although total inhibition was not achieved, Hes1 protein also decreased significantly when cells were treated with GSIs, especially with GSI-XXI ( Figure 3C ). No significant effect was observed when cells were treated with GSI-X or DAPT (not shown).
Notch pathway inhibition severely impairs cell mobility and invasiveness in RMS cells
When the 3 rhabdomyosarcoma cell lines were treated with GSIs, a significant reduction was observed in their mobility that could be measured in a wound-healing assay ( Figure 4 ). The delay observed is illustrated in figure 4A for the cell line RH-30. 
Down-regulation of Notch pathway has no noticeable effect on cell cycle and apoptosis
Notch pathway inhibition had no significant effect on cell cycling and apoptosis, and all the drugs applied (in a 3 days treatment) produced the same results in treated and nontreated RMS cells (data not shown), confirming that the inhibition observed in cell motility and invasion can not be attributable to changes in cell proliferation or in apoptosis. Moreover, the major cause of death in these patients is the formation of distant metastasis. The cellular components that control metastasis in RMS should be identified before the development of targeted therapies focused on reducing metastasis in this neoplasia.
Specificity (dnMAML1)
In this report, we provide evidence of Notch pathway expression and activation in RMS. One criterion to be met before a possible role of a pathway in a tissue can be considered is that this pathway must be expressed and activated in that tissue. It is noteworthy that all RMS tumors (n=37) analyzed presented expression of several Notch receptors and downstream Notch targets. Upregulation of Notch2 was particularly striking while upregulation of Notch3, Hes1 and Hey1 was also significant. transcription factor. Using this methodology, the effects seen on cells were practically identical to those observed with GSI treatment, which confirms more specifically that Notch inhibition suffices to produce the effects described with GSI treatment, particularly on invasiveness.
Although our study demonstrates a critical role of the Notch pathway in the activation of the process that leads to cell mobility and invasiveness in cell culture, further study will be needed in RMS to elucidate its implications in the more intricate tumor microenvironment. In our opinion, one of the challenges for the future is to create RMS animal models to characterize the pathway in vivo and attempt the possible use of GSIs -while avoiding toxicity -as a possible complementary targeted therapy against RMS, particularly in cases with a high probability of relapse. 
